On October 27, 2014, District Court Judge Amy J. St. Eve of the Northern District of Illinois found in an 80 page opinion that Mylan’s proposed generic drug product infringes all of the asserted claims of The Medicines Company’s U.S. Patent No. 7,582,727 (the “’727 patent”). She further held that the same claims of the ’727 patent were not invalid or unenforceable. The ’727 patent is listed in the FDA’s Orange Book as covering The Medicines Company’s drug product, Angiomax®, which is indicated for use as an anticoagulant during coronary angioplasty procedures.
On June 23, 2014, U.S. District Judge Stanley R. Chesler of the District of New Jersey issued a summary judgment decision, which granted FLH client Shire LLC’s motion for summary judgment that eighteen claims of four patents are valid and infringed. The patents-in-suit are listed in the FDA’s Orange Book as covering Shire’s drug Vyvanse® (lisdexamfetamine dimesylate), which is indicated as a treatment for attention deficit hyperactivity disorder (ADHD).